免疫|2021 AACR Week1 落幕：靶向、免疫多款新药盛大绽放( 三 )
参考文献：
1.D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy：results from a phase Ⅱ study.
2.BLU-945,a fourth-generation,potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor with intracranial activity,demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer.
3.NUV-655 is a selective,brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation.
4.1465-NUV-520 is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation.
5.https://www.aacr.org/blog/2021/04/12/aacr-annual-meeting-2021-novel-approaches-to-enhance-immunotherapy/.
6. Thomas Urban Marron, et al. An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001).
推荐阅读
- 糖尿病肾脏病|中国糖尿病肾脏病防治指南（2021年版）发布，要点一览！
- 2型糖尿病|2021新血糖标准已更正，更改为4.4-7.0mmolL？看专家怎么说
- 人类免疫缺陷病毒|深港团队开发艾滋病新抗体：动物实验中能100％预防HIV
- 苔丝·安德拉德|丈夫感染新冠住进ICU，妻子却没事，有人天生对新冠免疫？
- 新冠病毒|新冠病毒，能像天花一样被根除吗？
- 糖尿病|2021年版“中国糖尿病肾脏防治指南”发布，四个用药重点抢先看！
- 新冠|丈夫感染新冠住进ICU，妻子却没事，有人天生对新冠免疫？
- 核酸检测|最新消息！有调整！关于核酸检测
- 无力|老公突然双腿无力，接连摔了3跤
- 度伐利尤单抗|O、K折戟，I、T迎难而上，SCLC免疫治疗不再药荒